Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2019-07-22 Director's Dealing
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice MT 5 pages 326.8KB
Director's Dealing Classification · 100% confidence The document is an ASX/Media Release dated 23 July 2019 regarding a Change of Directors Interest Notice for Michael Thurn. It details the correction of an omission in a previous Directors Interest Notice and provides specifics about the director's securities holdings and changes. The document references Listing Rule 3.19A and includes an Appendix 3Y form, which is a standard form for notifying changes in directors' interests in securities. There is no financial report, earnings data, or management discussion present. The content is focused on insider share transactions by a company director. Therefore, this document fits the category of Director's Dealing (DIRS). The document length and detail support a confident classification.
2019-07-22 English
Initial Director's Interest Notice 2 pages 140.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including unlisted options held by the director and related parties. The document is a formal notification of a director's personal share transactions or interests. It does not contain financial statements, earnings data, or management discussion. The content matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on director interests, confirming it is not a full report or announcement of a report. Therefore, the correct classification is DIRS.
2019-07-22 English
Exercise Price of Options 2 pages 151.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX/Media Release dated 18 July 2019 from Botanix Pharmaceuticals Limited. It announces the exercise price of Incentive Options to be considered at a General Meeting on the same day. The content focuses on the pricing of options and references the Notice of Meeting released earlier. There is no detailed financial data, no full report, and the document is relatively short (3539 characters). It is an announcement related to capital structure changes (grant of options) rather than the full report or meeting materials. Therefore, it fits best under Capital/Financing Update (CAP).
2019-07-17 English
Results of Meeting 2 pages 469.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX/Media Release dated 18 July 2019 reporting the results of a General Meeting of Botanix Pharmaceuticals Limited. It details the resolutions passed, voting results, and proxy information. There is no financial data, no detailed report, or comprehensive analysis. The document is a formal announcement of voting results from a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3627 characters, which is relatively short and consistent with a voting results announcement rather than a full report or presentation.
2019-07-17 English
Vince Ippolito appointed as Botanix Executive Chairman 2 pages 157.7KB
Board/Management Information Classification · 100% confidence The document is an ASX/Media Release dated 18 July 2019 announcing the appointment of Vince Ippolito as Executive Chairman of Botanix Pharmaceuticals. It details management changes, including the stepping down of the interim Non-Executive Chairman and continuation of a board member. There is no financial data, no report attached or referenced as being published, and no mention of shareholder voting results beyond approval of remuneration matters. The content focuses on board and management changes, which fits the Board/Management Information category. The document length is under 5,000 characters, but it is not a report publication announcement or regulatory filing; it is a direct announcement of management changes. Therefore, the appropriate classification is MANG (Board/Management Information).
2019-07-17 English
Appendix 3B 12 pages 294.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including unlisted options, their terms, issue prices, and compliance with ASX rules. It references specific ASX rules (e.g., Rule 7.1, 7.1A) and includes sections on quotation of securities and calculation of placement capacity. The content is consistent with a formal announcement of new securities issuance and application for quotation on the ASX, which aligns with capital raising or financing activities. There is no indication that this is a full financial report, audit, or management discussion. The document is not a brief announcement of a report publication but a substantive filing about capital changes. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP).
2019-07-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.